Benitec Biopharma
BNTC
21 hedge funds and large institutions have $1.55M invested in Benitec Biopharma in 2022 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 1 reducing their positions, and 5 closing their positions.
600% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 1
0% more funds holding
Funds holding: 21 → 21 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
0.17% less ownership
Funds ownership: 1.14% → 0.96% (-0.17%)
40% less capital invested
Capital invested by funds: $2.6M → $1.55M (-$1.05M)
89% less call options, than puts
Call options by funds: $1K | Put options by funds: $9K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Barclays
London,
United Kingdom
|
+$106K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$73.7K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$68.3K |
| 4 |
VF
Virtu Financial
New York
|
+$64.8K |
| 5 |
Millennium Management
New York
|
+$34.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
Atom Investors
Austin,
Texas
|
-$87K |
| 2 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$57K |
| 3 |
BlackRock
New York
|
-$46K |
| 4 |
MHR
Matthew Hamilton Rosenberg
|
-$1K |
| 5 |
Bank of New York Mellon
New York
|
-$140 |
BNTC Hedge Fund Activity: Q2 2022 in Review
21 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Benitec Biopharma (BNTC) for Q2 2022, worth a combined $1.55M — down 40% from $2.6M a quarter earlier.
Fund positioning in BNTC was balanced in Q2 2022: 5 funds opened new positions, 5 closed out, 7 added to existing stakes and 1 trimmed.
The largest buyer was Barclays, adding an estimated $106K. The largest seller was Atom Investors, exiting entirely with an estimated $87K sold.
- 21 institutional investors held Benitec Biopharma (BNTC) as of Q2 2022, unchanged from Q1 2022.
- Funds reported $1.55M of Benitec Biopharma stock for Q2 2022, down 40% quarter-over-quarter.
- 5 funds opened new Benitec Biopharma positions in Q2 2022 and 5 closed out, a net change of 0 holders.
- The largest Benitec Biopharma buyer in Q2 2022 was Barclays, an estimated $106K added.
- The largest Benitec Biopharma seller in Q2 2022 was Atom Investors, an estimated $87K sold.
Based on aggregated 13F filings for Q2 2022.